30 min listen
AviadoBio: Bold and Courageous
FromVital Science
ratings:
Length:
31 minutes
Released:
Jan 17, 2023
Format:
Podcast episode
Description
Recent advancements in research has led to the development of effective therapeutics to combat neurodegenerative diseases, giving patients a renewed sense of hope there will ultimately be a more effective treatment.CEO Lisa Deschamps and her team at AviadoBio are among those conducting research in the space, but they’re doing things a little differently. They’ve been given a unique drug designation by the FDA to develop a treatment for frontotemporal dementia (FTD), a crippling neurodegenerative disorder that affects neuron production in people under 65. It may be a “bold and courageous” undertaking, but the benefits could affect future generations to come.Join us as we take a look at the motivation behind the work AviadoBio is doing, what makes their therapy unique, and Lisa’s vision for their future.Show Notes
AviadoBio
S4, E01: Project ALS: Fueled by Love
S3, E01: A Synergistic Approach to Treating Huntington's Disease
Charles River | Neuroscience
Charles River | Gene Therapy for Neurological Disorders
Charles River| GEne Therapy Services
AviadoBio
S4, E01: Project ALS: Fueled by Love
S3, E01: A Synergistic Approach to Treating Huntington's Disease
Charles River | Neuroscience
Charles River | Gene Therapy for Neurological Disorders
Charles River| GEne Therapy Services
Released:
Jan 17, 2023
Format:
Podcast episode
Titles in the series (48)
Leading the Way: Jake Glanville talks leadership and the COVID-19 fight. by Vital Science